FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

Core Insights - Telix Pharmaceuticals reported a revenue of US$803.8 million for FY 2025, marking a 56% increase compared to FY 2024, and exceeded its full-year guidance [6][25] - The company achieved positive adjusted EBITDA of US$39.5 million, despite a non-material loss before tax of US$5.3 million due to increased operating expenditures [6][8] - Telix is focusing on expanding its Precision Medicine segment and has prioritized R&D investments towards late-stage assets, with US$98 million allocated to therapeutics [5][7] Financial Performance - Total revenue for FY 2025 was US$803.8 million, up from US$516.6 million in FY 2024 [8] - Gross profit increased to US$426.4 million, with a stable gross margin of 64% [8] - Research and development expenses rose to US$171.2 million from US$127.9 million in the previous year [8] - Selling and marketing expenses increased to US$96.8 million, reflecting investments in global commercial infrastructure [8] Segment Performance - The Precision Medicine segment saw a revenue increase of 22% year-over-year, driven by higher volumes of Illuccix® and the successful launch of Gozellix® in the U.S. [6][8] - The Telix Manufacturing Solutions (TMS) segment reported total revenue of US$238.4 million, with a positive adjusted EBITDA contribution of US$1.2 million from RLS [6][8] - RLS's revenue included US$170.1 million from third-party product sales and service fees, indicating strong growth in sales [6][8] R&D and Regulatory Developments - Telix invested US$98 million in its therapeutics pipeline, achieving significant milestones in clinical trials for prostate, kidney, and brain cancer treatments [5][9] - Regulatory approvals were received for multiple trials, including TLX250-Tx for metastatic clear cell renal cell carcinoma and TLX101-Tx for recurrent glioblastoma [9] - The company plans to continue expanding its product pipeline and has filed for marketing authorization for TLX101-Px in Europe and is finalizing the NDA for the U.S. [6][9] Future Guidance - For FY 2026, Telix projects revenue between US$950 million and US$970 million, reflecting confidence in sustaining growth momentum [7][9] - The company anticipates R&D expenditures of US$200 million to US$240 million to support its therapeutic pipeline [9]